[13] Charles Bankhead, a senior editor at MedPageToday, covered the topic, outlining the paper's primary point, which was the high prevalence of research articles demonstrating findings that deviated from the accepted standard of treatment at the time.
[14] Separately, "Retraction Watch" reported on Prasad's personal remarks about the paper, saying "For a long time, we were interested by what we believe to be a pervasive problem in modern medicine.
"[15] Matthew Hoffman, writing in 2012 for MedPageToday's KevinMD covered a paper by Prasad and colleagues on "When to abandon ship" when it comes to failing medical practices and treatments.
[16][17] Hoffman builds on the authors' proposed barriers to market entrance, such as evidence of effectiveness in large randomized controlled studies before broad usage, and links them to the insidious aspects of healthcare, such as profit and status.
The JAMA Internal Medicine article received widespread media attention, with Reuters' Genevra Pittman interviewing Prasad about his further views on the intervention.
[23] Skeptics David Gorski and Steven Novella published criticisms of and counter-arguments to Prasad's stance, pointing out the perils of not challenging alternative medicine during a pandemic.
[24][25] In October 2021, Prasad prompted social media controversy when he published a blog post comparing the U.S. COVID-19 pandemic response to the beginnings of Adolf Hitler's Third Reich.
[27] However, physician Jonathan Howard noted that Prasad was selectively omitting the risks of COVID disease[28] which would not be consistent with the tenets of medical informed consent.
In January 2022, the conservative periodical City Journal published an opinion piece by Prasad in which he attempted to demonstrate that the American public health organizations were not being honest in their response to the COVID-19 pandemic.
[38] However, according to physician David Gorski, Prasad again demonstrated insufficient understanding of the limitations of these randomized controlled trials as well as how the NIH's funding decisions work.